Eurobiomed has organized a Biorezo dedicated to immunology and oncology on Tuesday, February 3, 2025, at DocCity in Marseille, fields in which the cluster has been actively engaged since 2012. Five Marseille-based start-ups developing innovative immunotherapies have presented their projects to the Eurobiomed community of health innovators. The event was mentored by Jaime Arango, Chief Financial Officer of Adcytherix, and Pierre d’Epenoux, former CEO of ImCheck Therapeutics.
« Not first in class, best in class »
Adcytherix has illustrated the dynamism of the Marseille ecosystem. « The company is very young, it started in March 2024, and has been built by a very experienced team, » explains Jaime Arango, Chief Financial Officer of Adcytherix. Created with thirty million euros in seed funding, with the goal of having a product in the clinic in 2026 and first patients in the coming months, the company closed its Series A in October 2025 for an amount of 105 million euros. Adcytherix develops Antibody Drug Conjugates. « The first product is 100% stable; it isn’t first in class, it is best in class, » specified Jaime Arango.
Kahimmune Therapeutics explores the dark genome
Kahimmune Therapeutics is developing an innovative approach in the field of cancer vaccines. « The company was created in November 2025 and yesterday has just announced a licensing agreement with SATT and Gustave Roussy, » indicates Philippe Villain-Guillot, founder of Kahimmune Therapeutics. « Our mission is to develop breakthrough companion mRNA cancer vaccines; we are creating a platform to mine the dark genome and uncover novel therapy-specific neoantigens, » he explained. This approach is based on recent scientific observations. « New studies show that cancer vaccines work when they are associated with other therapies, » emphasized Philippe Villain-Guillot.
« I transplanted Celsiege from New York to Marseille »
Celsiege Biosciences demonstrated the attractiveness of the Marseille territory for innovative immunology companies. « I transplanted Celsiege from New York to Marseille, a big shout out for that to Eurobiomed, » declared Sree Kant, CEO of Celsiege Biosciences. The company is developing a plug and play platform to enable pipeline development. “We are using the human body to create immunotherapies” specified Sree Kant.
Three functional prototypes for Mohican
Mohican, founded in November 2025, offers a technological innovation in the field of microfluidics. The start-up has developed microfluidics and microprinting technology to print molecules. « The idea is to do cheap microassays, » explained Olivier Theodoly, of Mohican. The company already has three functional prototypes, demonstrating the technological maturity of its approach.
Clinical trial targeted by 2029 for Orthos Therapeutics
Orthos Therapeutics is tackling a major medical need in pediatric oncology. « We are here for the ones, children and young adults, fighting T-cell Acute Lymphoblastic Leukemia, » stated Guillaume Dubreuil, representative of Orthos Therapeutics. Currently, fewer than 25% of patients have a 5-year survival rate for this pathology. The company is developing a promising small molecule, with encouraging results: 50% survival has been achieved in certain models without observed toxicity. « Our goal is to reach clinical trials by 2029. We will be launching the company in 2026, » specified Guillaume Dubreuil.
Massalia Therapeutics targets glioblastoma
Massalia Therapeutics focuses on one of the most difficult pathologies to treat in oncology. « Our first focus is glioblastoma, » indicated Gary Brandam, representative of Massalia Therapeutics. The company has developed an innovative therapeutic approach. « We have developed an antibody which is only targeting the soluble form, it will not only have an effect on the tumor growth but it’s also able to kill the tumor in the brain, » explained Gary Brandam. Public authorities have recognized this innovation: « We got an i-Lab last year, » he added.
« Great data plus great talents equals money »
Pierre d’Epenoux, one of the mentors of the event and former CEO of ImCheck Therapeutics, shared his experience with the young entrepreneurs present. « ImCheck was built nine years ago from an academic lab, » recalled Pierre d’Epenoux, CEO of ImCheck Therapeutics. His message to entrepreneurs is clear and pragmatic. « If you have great data and great talents, you will raise money, » he concluded.
This Biorezo has illustrated Eurobiomed’s ability to bring together key players and highlight cutting-edge innovation within the HealthTech ecosystem of the southern regions. Eurobiomed warmly thanks its mentors Jaime Arango from Adcytherix and Pierre d’Epenoux from ImCheck Therapeutics, as well as its sponsors Icosa and CEPAC for their contribution to this event.
